PL3848028T3 - Sposoby leczenia stanów dotyczących oczu - Google Patents

Sposoby leczenia stanów dotyczących oczu

Info

Publication number
PL3848028T3
PL3848028T3 PL20212556.3T PL20212556T PL3848028T3 PL 3848028 T3 PL3848028 T3 PL 3848028T3 PL 20212556 T PL20212556 T PL 20212556T PL 3848028 T3 PL3848028 T3 PL 3848028T3
Authority
PL
Poland
Prior art keywords
methods
treating ocular
ocular conditions
conditions
treating
Prior art date
Application number
PL20212556.3T
Other languages
English (en)
Polish (pl)
Inventor
Douglas Michael ACKERMANN Jr.
James Loudin
Kenneth J. Mandell
Original Assignee
Oyster Point Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55748136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3848028(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oyster Point Pharma, Inc. filed Critical Oyster Point Pharma, Inc.
Publication of PL3848028T3 publication Critical patent/PL3848028T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
PL20212556.3T 2014-10-20 2015-10-19 Sposoby leczenia stanów dotyczących oczu PL3848028T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462066280P 2014-10-20 2014-10-20
US201562100844P 2015-01-07 2015-01-07

Publications (1)

Publication Number Publication Date
PL3848028T3 true PL3848028T3 (pl) 2024-11-18

Family

ID=55748136

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20212556.3T PL3848028T3 (pl) 2014-10-20 2015-10-19 Sposoby leczenia stanów dotyczących oczu

Country Status (21)

Country Link
US (14) US9532944B2 (enExample)
EP (3) EP4413974A3 (enExample)
JP (3) JP6873906B2 (enExample)
KR (2) KR102511955B1 (enExample)
CN (3) CN107106542B (enExample)
AU (2) AU2015336216B2 (enExample)
BR (2) BR112017008097B1 (enExample)
CA (1) CA2965129C (enExample)
DK (2) DK3848028T5 (enExample)
EA (1) EA035335B1 (enExample)
ES (2) ES2848977T5 (enExample)
FI (1) FI3848028T3 (enExample)
IL (3) IL318427A (enExample)
MX (2) MX392383B (enExample)
MY (1) MY186870A (enExample)
PH (1) PH12017500602A1 (enExample)
PL (1) PL3848028T3 (enExample)
PT (2) PT3209295T (enExample)
SG (2) SG10202011669PA (enExample)
WO (1) WO2016064759A1 (enExample)
ZA (1) ZA201703467B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4413974A3 (en) 2014-10-20 2024-10-09 Oyster Point Pharma, Inc. Methods of treating ocular conditions
KR102512777B1 (ko) * 2016-04-07 2023-03-23 오이스터 포인트 파마 인코포레이티드 안구 장애의 치료 방법
TW202019424A (zh) * 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
CN112638364A (zh) 2018-07-10 2021-04-09 奥伊斯特普安生物制药公司 用于治疗眼部病症的正向别构调节剂和烟碱型乙酰胆碱受体激动剂的组合
TW202206078A (zh) 2020-04-28 2022-02-16 美商奧伊斯特普安生物製藥公司 局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染
WO2025037323A1 (en) * 2023-08-12 2025-02-20 Pavan Kumar Kothapuvari Pharmaceutical compositions for treatment of dry eye disease and associated disorders
DE102023208057A1 (de) * 2023-08-23 2025-02-27 Ursapharm Arzneimittel Gmbh Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
DE60209929T2 (de) 2001-11-29 2006-11-16 Pfizer Products Inc., Groton Succinatsalze von 58;8;14-triatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2,11,3,5,7,9,-pentaen und pharmazeutische zusammensetzungen
AU2003269413A1 (en) * 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
WO2006040680A1 (en) * 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
DK1809238T3 (da) * 2004-11-09 2010-01-25 Novagali Pharma Sa Ophthalmiske emulsioner indeholdende et immunosuppressivt middel
WO2006100075A2 (en) * 2005-03-22 2006-09-28 Niconovum Ab Use of an artificial sweetener to enhance absorption of nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
US20070054843A1 (en) 2005-08-26 2007-03-08 Yeomans David C Methods for treatment of headaches by administration of oxytocin
CA2949643C (en) 2005-09-27 2018-05-15 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
TWI404532B (zh) 2006-11-02 2013-08-11 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
AU2008211613B2 (en) * 2007-02-02 2013-05-23 Pfizer Products Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators
EP1977746B8 (en) * 2007-04-02 2014-09-24 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) * 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US20090215787A1 (en) 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
MX2010009727A (es) 2008-03-05 2010-09-28 Targacept Inc Amidas selectivas del subtipo del receptor nicotinico de acetilcolina de diazabicicloalcanos.
CN102143963A (zh) 2008-09-05 2011-08-03 塔加西普特公司 二氮杂双环辛烷的酰胺及其应用
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
MX2011005611A (es) 2008-12-01 2011-09-15 Targacept Inc Sintesis y formas de sales novedosas de (r)-5-((e)-2-(pirrolidin-3 -il-vinil)pirimidina.
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) * 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
CA2841416A1 (en) * 2011-06-15 2012-12-20 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
BR112013032044A2 (pt) * 2011-06-30 2016-12-13 Toray Industries antiprurítico
CN103930112B (zh) * 2011-10-20 2018-11-09 诺华股份有限公司 预测对α7烟碱型乙酰胆碱受体激活剂疗法的响应的生物标志物
WO2013080196A1 (en) * 2011-11-30 2013-06-06 D.E.S. Diagnostics Ltd. Dry eye diagnostic
ES2426517B1 (es) * 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
PT2968368T (pt) 2013-03-15 2017-11-15 Glia Llc Administração craniana de substâncias farmacêuticas
EP2986339A4 (en) 2013-04-19 2016-12-21 Oculeve Inc Nasal stimulation devices and methods
EP4413974A3 (en) 2014-10-20 2024-10-09 Oyster Point Pharma, Inc. Methods of treating ocular conditions
KR102512777B1 (ko) 2016-04-07 2023-03-23 오이스터 포인트 파마 인코포레이티드 안구 장애의 치료 방법
TW202019424A (zh) 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
CN112638364A (zh) 2018-07-10 2021-04-09 奥伊斯特普安生物制药公司 用于治疗眼部病症的正向别构调节剂和烟碱型乙酰胆碱受体激动剂的组合

Also Published As

Publication number Publication date
DK3209295T3 (da) 2021-03-01
US11224598B2 (en) 2022-01-18
US20170239244A1 (en) 2017-08-24
US20160106744A1 (en) 2016-04-21
EP3209295A1 (en) 2017-08-30
EP3209295B1 (en) 2020-12-09
JP2021038250A (ja) 2021-03-11
US20200246336A1 (en) 2020-08-06
US20250275963A1 (en) 2025-09-04
CA2965129A1 (en) 2016-04-28
US20250255865A1 (en) 2025-08-14
CN111956650A (zh) 2020-11-20
US20230226052A1 (en) 2023-07-20
EP3209295B2 (en) 2023-12-06
EP3848028A1 (en) 2021-07-14
MY186870A (en) 2021-08-26
WO2016064759A1 (en) 2016-04-28
IL251769A0 (en) 2017-06-29
DK3848028T3 (da) 2024-08-26
US20160106745A1 (en) 2016-04-21
KR102511955B1 (ko) 2023-03-22
US11903942B2 (en) 2024-02-20
CN111956803B (zh) 2025-10-31
AU2015336216B2 (en) 2020-05-21
BR122022025737B1 (pt) 2023-12-26
AU2020213351B2 (en) 2023-04-06
PT3209295T (pt) 2021-02-05
ZA201703467B (en) 2023-12-20
JP2023024574A (ja) 2023-02-16
US9504644B2 (en) 2016-11-29
CN107106542A (zh) 2017-08-29
SG10202011669PA (en) 2020-12-30
KR20170086040A (ko) 2017-07-25
KR20230042144A (ko) 2023-03-27
US10456396B2 (en) 2019-10-29
MX2017005064A (es) 2018-02-23
MX2022005888A (es) 2022-06-14
IL293188A (en) 2022-07-01
US9597284B2 (en) 2017-03-21
IL293188B2 (en) 2025-06-01
JP6873906B2 (ja) 2021-05-19
KR102601505B1 (ko) 2023-11-14
JP7257371B2 (ja) 2023-04-13
EA201790893A1 (ru) 2018-01-31
AU2020213351A1 (en) 2020-08-27
JP7502404B2 (ja) 2024-06-18
US11903941B2 (en) 2024-02-20
EP3848028B9 (en) 2024-10-16
JP2017531044A (ja) 2017-10-19
BR112017008097B1 (pt) 2023-03-28
SG11201703135XA (en) 2017-05-30
BR112017008097A2 (pt) 2018-02-20
US9532944B2 (en) 2017-01-03
US20230226054A1 (en) 2023-07-20
PT3848028T (pt) 2024-09-20
FI3848028T3 (fi) 2024-08-21
US20250235449A1 (en) 2025-07-24
EA035335B1 (ru) 2020-05-28
IL251769B (en) 2022-06-01
US11911380B2 (en) 2024-02-27
CA2965129C (en) 2024-03-12
IL293188B1 (en) 2025-02-01
MX392383B (es) 2025-03-24
US11903943B2 (en) 2024-02-20
CN111956650B (zh) 2024-06-04
AU2015336216A1 (en) 2017-06-08
EP3209295A4 (en) 2018-05-23
US20230226053A1 (en) 2023-07-20
US20160106665A1 (en) 2016-04-21
ES2848977T5 (es) 2024-06-06
EP3848028B1 (en) 2024-05-29
IL318427A (en) 2025-03-01
EP4413974A3 (en) 2024-10-09
ES2986830T3 (es) 2024-11-12
DK3848028T5 (da) 2025-01-20
CN111956803A (zh) 2020-11-20
US20160106746A1 (en) 2016-04-21
US20220233528A1 (en) 2022-07-28
DK3209295T4 (da) 2024-02-26
CN107106542B (zh) 2020-05-08
US9504645B2 (en) 2016-11-29
PH12017500602A1 (en) 2017-09-04
EP4413974A2 (en) 2024-08-14
ES2848977T3 (es) 2021-08-13
US20240173318A1 (en) 2024-05-30

Similar Documents

Publication Publication Date Title
IL283561B (en) Methods for treating eye diseases
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
GB201701673D0 (en) Methods of well treatment
IL253244A0 (en) Methods for treating retinal diseases
PL3851537T3 (pl) Leczenie hiperbilirubinemii
IL246791A0 (en) Compositions and methods for treating eye diseases
ZA201700416B (en) Methods for treating or preventing ophthalmological conditions
ZA201706059B (en) Method of treatment with tradipitant
IL290069A (en) Methods for treating eye conditions
GB201410116D0 (en) Method of treatment
IL251769A0 (en) Methods for treating eye conditions
IL253028A0 (en) treatment method
GB201416832D0 (en) Methods of treatment
IL253847A0 (en) Methods of treating diseases
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201512139D0 (en) Methods of treatment
GB201407806D0 (en) Treatment of fibrosis
GB201421980D0 (en) Method of treatment
GB201421982D0 (en) Method of treatment
GB201415331D0 (en) Method of treatment
GB201414780D0 (en) Method Of Treatment
HK1234660A1 (en) Method of treating skin conditions
GB201511017D0 (en) Method of treatment
AU2014905194A0 (en) Method of Treatment
AU2014904907A0 (en) Method of Treatment